Gilead Sciences, Inc. (NASDAQ: GILD) reported total revenue of $6.4 billion for the first quarter of 2023, which was down 4% year-over-year.

Net income attributable to Gilead was $1 billion, or $0.80 per share, compared to $19 million, or $0.02 per share, last year. Adjusted EPS amounted to $1.37.
For the full year of 2023, the company expects adjusted EPS of $6.60-7.00.
Prior performance

Most Popular
Infographic: Amazon (AMZN) Q4 2024 earnings beat estimates; sales rise 10%
E-commerce giant Amazon.com Inc. (NASDAQ: AMZN) on Thursday reported higher sales and profit for the fourth quarter of 2024. Earnings also beat analysts' estimates. Net sales increased to $187.8 billion
Philip Morris (PM) delivers strong performance in 4Q24 helped by smoke-free strength
Shares of Philip Morris International Inc. (NYSE: PM) jumped 10% on Thursday after the company delivered better-than-expected earnings results for the fourth quarter of 2024 and provided an encouraging outlook
Highlights of Bristol-Myers Squibb’s Q4 2024 earnings report
Biotechnology company Bristol Myers Squibb (NYSE: BMY) reported lower profit for the fourth quarter of 2024, despite an increase in revenue. Net income attributable to shareholders was $72 million or